Alexis Boaz
CMS Names Its First Ten Negotiated Part D Drugs: Inflation Reduction Act Updates
Health Care and Life Sciences ·
Texas Federal Court Issues Fourth Ruling Invalidating Parts of the Administration’s No Surprises Act Regulations
Health Care and Life Sciences ·
TAKE TWO: CMS’s Second Attempt to Streamline Breakthrough Device Coverage Limited to 5 Devices Per Year
Health Care and Life Sciences ·
More Federal Action in the Pharmaceutical Sector as PBM Bill Advances in the Senate
Health Care and Life Sciences ·